/
MTNB
$0.66+$0.02 (+3.36%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$4.1M
6M shares
52-week range
$0.48 – $3.09
7% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
XASE
CS
Borrow rate
0.46%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-38.08
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $119.8K | $89.8K | $158.3K | $33.0K | $3.2M | $1.1M | $0 | $0 |
| Cost of revenue | $6.8M | $11.2M | $14.4M | $14.6M | $16.7M | $941.0K | $972.0K | $456.0K |
| Gross profit | −$6.7M | −$11.1M | −$14.2M | −$14.6M | −$13.5M | $1.1M | −$972.0K | −$456.0K |
| Gross margin | -5568.0% | -12409.0% | -8968.8% | -44090.9% | -423.1% | 100.0% | — | — |
| R&D | $6.8M | $11.2M | $14.4M | $14.6M | $16.7M | $14.5M | $11.4M | $85.0K |
| Operating income | −$14.6M | −$18.9M | −$24.2M | −$24.7M | −$24.6M | −$23.8M | −$24.6M | −$7.0M |
| EBITDA | −$14.4M | −$18.6M | −$23.9M | −$23.0M | −$20.6M | −$22.0M | −$19.2M | −$9.9M |
| Net income | −$14.1M | −$17.4M | −$22.4M | −$23.3M | −$21.0M | −$22.9M | −$24.3M | −$10.3M |
| Net margin | -11760.4% | -19343.4% | -14177.0% | -70554.5% | -658.6% | -2093.2% | — | — |
| EPS (diluted) | -7.18 | -5.37 | -5.23 | -5.04 | -3.00 | -5.28 | -4.98 | -2.00 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $93M | $-5.00 | $-5.00–$-5.00 | 1 |
| 2027 | $45M | $-2.50 | $-2.50–$-2.50 | 1 |
| 2028 | $120M | $11.00 | $11.00–$11.00 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.43
Price
$0.66
Implied downside
-35%
Peer comparison
Matinas BioPharma Holdings, Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
www.matinasbiopharma.com- Employees
- 2
- IPO / List date
- Jul 21, 2014
- HQ
- BEDMINSTER, NJ
Held by traders on TradeandTell
No one on the platform currently holds MTNB.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 28,570 | $14.3K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-09-03 | 1-for-50reverse |
Recent trades on TradeandTell
No one on the platform has traded MTNB yet.
